IL312551B2 - GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer - Google Patents

GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer

Info

Publication number
IL312551B2
IL312551B2 IL312551A IL31255124A IL312551B2 IL 312551 B2 IL312551 B2 IL 312551B2 IL 312551 A IL312551 A IL 312551A IL 31255124 A IL31255124 A IL 31255124A IL 312551 B2 IL312551 B2 IL 312551B2
Authority
IL
Israel
Prior art keywords
cancer
compound
xaa
tumors
grpr
Prior art date
Application number
IL312551A
Other languages
English (en)
Hebrew (he)
Other versions
IL312551A (en
IL312551B1 (en
Inventor
Maina-Nock Theodosia
Artur Nock Berthold
De Jong Hendriks Marion
Original Assignee
Advanced Accelerator Applications Usa Inc
Advanced Accelerator Applications Int Sa
Theodosia Maina Nock
Artur Nock Berthold
De Jong Hendriks Marion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Usa Inc, Advanced Accelerator Applications Int Sa, Theodosia Maina Nock, Artur Nock Berthold, De Jong Hendriks Marion filed Critical Advanced Accelerator Applications Usa Inc
Publication of IL312551A publication Critical patent/IL312551A/en
Publication of IL312551B1 publication Critical patent/IL312551B1/en
Publication of IL312551B2 publication Critical patent/IL312551B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL312551A 2012-09-25 2013-09-25 GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer IL312551B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Publications (3)

Publication Number Publication Date
IL312551A IL312551A (en) 2024-07-01
IL312551B1 IL312551B1 (en) 2025-08-01
IL312551B2 true IL312551B2 (en) 2025-12-01

Family

ID=49887190

Family Applications (4)

Application Number Title Priority Date Filing Date
IL312551A IL312551B2 (en) 2012-09-25 2013-09-25 GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer
IL276300A IL276300B2 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
IL237844A IL237844B (en) 2012-09-25 2015-03-19 Radiolabeled grpr antagonists for diagnostic imaging and treatment of grpr-positive cancer
IL256649A IL256649B (en) 2012-09-25 2017-12-28 Grpr antagonists for the detection, diagnosis and treatment of grpr-positive cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL276300A IL276300B2 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
IL237844A IL237844B (en) 2012-09-25 2015-03-19 Radiolabeled grpr antagonists for diagnostic imaging and treatment of grpr-positive cancer
IL256649A IL256649B (en) 2012-09-25 2017-12-28 Grpr antagonists for the detection, diagnosis and treatment of grpr-positive cancer

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102314293B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL312551B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
PL2900279T3 (pl) * 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
DK3568205T3 (da) 2017-01-12 2023-10-09 Radiomedix Inc Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater
CN113195005B (zh) * 2018-10-12 2023-07-21 国际先进加速器应用公司 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法
CN114728088A (zh) * 2019-09-16 2022-07-08 诺华股份有限公司 稳定的浓缩的放射性药物组合物
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識grprアンタゴニスト
EP4076541A1 (en) * 2019-12-19 2022-10-26 Technische Universität München Modified grpr antagonist peptides for imaging and therapy of cancer
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
US4943561A (en) 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) * 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IL96216A0 (en) 1989-11-06 1991-08-16 Erba Carlo Spa Peptide derivatives,their preparation and pharmaceutical compositions containing them
EP0626973A1 (en) 1992-02-07 1994-12-07 Merrell Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US6545125B1 (en) 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
CA2526556C (en) 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
MX2013005697A (es) 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
PL2900279T3 (pl) * 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego

Also Published As

Publication number Publication date
IL256649B (en) 2020-08-31
IL276300B2 (en) 2024-10-01
IL276300A (en) 2020-09-30
AU2018204513B2 (en) 2019-05-23
AU2019216714B2 (en) 2021-04-08
BR112015006453A2 (https=) 2017-09-05
CA2886068A1 (en) 2014-04-03
JP7358430B2 (ja) 2023-10-10
AU2013323596C1 (en) 2020-10-15
AU2021201914B2 (en) 2024-09-05
RU2015115529A (ru) 2016-11-20
IL312551A (en) 2024-07-01
US20150265732A1 (en) 2015-09-24
RU2693465C2 (ru) 2019-07-03
RU2693465C9 (ru) 2020-08-14
JP6562838B2 (ja) 2019-08-21
JP2021191800A (ja) 2021-12-16
JP2019167365A (ja) 2019-10-03
JP7534498B2 (ja) 2024-08-14
AU2019216714A1 (en) 2019-09-05
PL2900279T3 (pl) 2020-05-18
US20220008568A1 (en) 2022-01-13
US12064490B2 (en) 2024-08-20
US20240366812A1 (en) 2024-11-07
LT2900279T (lt) 2019-11-11
MX2015003772A (es) 2015-11-09
US20210346528A1 (en) 2021-11-11
JP6997135B2 (ja) 2022-02-04
RU2019119378A (ru) 2020-10-23
AU2021201914A1 (en) 2021-04-29
AU2013323596A1 (en) 2015-04-02
US12064489B2 (en) 2024-08-20
EP2900279A1 (en) 2015-08-05
PT2900279T (pt) 2019-10-14
WO2014052471A1 (en) 2014-04-03
KR20150090886A (ko) 2015-08-06
US12064491B2 (en) 2024-08-20
IL237844B (en) 2018-01-31
HUE045724T2 (hu) 2020-01-28
MX362675B (es) 2019-01-30
EP2900279B1 (en) 2019-08-14
US20210346529A1 (en) 2021-11-11
SI2900279T1 (sl) 2019-12-31
AU2018204513C1 (en) 2020-10-15
BR112015006453B1 (pt) 2023-10-17
AU2018204513A1 (en) 2018-07-12
IL256649A (en) 2018-02-28
US20180133349A1 (en) 2018-05-17
KR102190005B1 (ko) 2020-12-15
KR20200139846A (ko) 2020-12-14
CA2886068C (en) 2021-06-22
US20200009276A1 (en) 2020-01-09
ES2745635T3 (es) 2020-03-03
US11083805B2 (en) 2021-08-10
JP2015533119A (ja) 2015-11-19
IL312551B1 (en) 2025-08-01
KR102314293B1 (ko) 2021-10-19
US9839703B2 (en) 2017-12-12
CA3114832A1 (en) 2014-04-03
HRP20191620T1 (hr) 2019-12-13
JP2023126440A (ja) 2023-09-07
EP3536347A1 (en) 2019-09-11
AU2013323596B2 (en) 2018-03-22
DK2900279T3 (da) 2019-09-30
IL276300B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
IL312551B2 (en) GRPR antagonists for detection, diagnosis and treatment of GRPR-positive cancer
DK2252628T3 (en) Bombesin analog peptide antagonist conjugates
Garayoa et al. Chemical and biological characterization of new Re (CO) 3/[99mTc](CO) 3 bombesin analogues
EP3089992A1 (en) Compositions and methods for imaging cancer
JP2023549469A (ja) 新規cxcr4標的化合物
Cantorias et al. MO tripeptide diastereomers (M= 99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals
Makris et al. Synthesis and evaluation of fac-[99mTc/Re (CO) 3]+ complexes with a new (N, S, N) bifunctional chelating agent: The first example of a fac-[Re (CO) 3 (N, S, N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide
KR20250007523A (ko) 가스트린 방출 펩티드 수용체(grpr)를 생체 내에서 영상화하고 grpr 관련 장애를 치료하기 위한 방사성 표지된 화합물
CA3153267A1 (en) Modified grpr antagonist peptides for imaging and therapy of cancer
WO2026083422A1 (en) Cyclic grpr binding peptides
WO2026058257A1 (en) Grpr binding peptides
Liu et al. Evaluation of a novel Tc-99m-labeled HYNIC-conjugated lactam bridge-cyclized alpha-MSH peptide for human melanoma imaging
WO2006114324A1 (en) Compounds comprising cyclized somatostatin receptor binding peptides